FACTIVE (gemifloxacin mesylate) by LG Chem Life Sciences is clinical pharmacology pharmacokinetics the pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg. Approved for infections caused by susceptible strains of the designated microorganisms in the conditions listed below, development of drug-resistant bacteria, maintain the effectiveness of factive and 3 more indications. First approved in 2003.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
FACTIVE (gemifloxacin mesylate) is an oral fluoroquinolone antibiotic approved in 2003 for treating respiratory and urinary tract infections caused by susceptible bacteria. It exhibits rapid absorption with peak plasma concentrations within 0.5-2 hours and achieves approximately 71% bioavailability. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, making it effective against gram-positive and gram-negative pathogens.
As FACTIVE approaches end-of-life, the brand team is likely contracting; careers here focus on managed decline and transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg. There was minimal accumulation of gemifloxacin following multiple oral doses up to 640 mg a day for 7 days (mean accumulation <20%). Following repeat oral…
Worked on FACTIVE at LG Chem Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Positions linked to FACTIVE are scarce (0 open roles identified), reflecting the product's late-lifecycle status and market contraction. Career growth on this product is limited; professionals are typically managing steady-state operations and preparing for post-LOE transitions. Opportunity lies in supporting managed decline and potentially identifying repositioning strategies in specialty segments.